{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:21:45Z","timestamp":1785475305873,"version":"3.56.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JP24249024, 16jm0410004j0005"],"award-info":[{"award-number":["JP24249024, 16jm0410004j0005"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20lm0203135"],"award-info":[{"award-number":["JP20lm0203135"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>BK-SE36\/CpG is a recombinant blood-stage malaria vaccine candidate based on the N-terminal <jats:italic>Plasmodium falciparum<\/jats:italic> serine repeat antigen5 (SE36), adsorbed to aluminium hydroxide gel and reconstituted, prior to administration, with synthetic oligodeoxynucleotides bearing CpG motifs. In healthy Japanese adult males, BK-SE36\/CpG was well tolerated. This study assessed its safety and immunogenicity in healthy malaria-exposed African adults and children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A double-blind, randomised, controlled, age de-escalating clinical trial was conducted in an urban area of Ouagadougou, Burkina Faso. Healthy participants (n=135) aged 21-45 years (Cohort 1), 5-10 years (Cohort 2) and 12-24 months (Cohort 3) were randomised to receive three vaccine doses (Day 0, 28 and 112) of BK-SE36\/CpG or rabies vaccine by intramuscular injection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred thirty-four of 135 (99.2%) subjects received all three scheduled vaccine doses. Vaccinations were well tolerated with no related Grade 3 (severe) adverse events (AEs). Pain\/limitation of limb movement, headache in adults and fever in younger children (all mild to moderate in intensity) were the most frequently observed local and systemic AEs. Eighty-three of BK-SE36\/CpG (91%) recipients and 37 of control subjects (84%) had Grade 1\/2 events within 28 days post vaccination. Events considered by the investigator to be vaccine related were experienced by 38% and 14% of subjects in BK-SE36\/CpG and control arms, respectively. Throughout the trial, six Grade 3 events (in 4 subjects), not related to vaccination, were recorded in the BK-SE36\/CpG arm: 5 events (in 3 subjects) within 28 days of vaccination. All serious adverse events (SAEs) (n=5) were due to severe malaria (52-226 days post vaccination) and not related to vaccination. In all cohorts, BK-SE36\/CpG arm had higher antibody titres after Dose 3 than after Dose 2. Younger cohorts had stronger immune responses (12\u201324-month-old &amp;gt; 5-10 years-old &amp;gt; 21-45 years-old). Sera predominantly reacted to peptides that lie in intrinsically unstructured regions of SE36. In the control arm, there were no marked fold changes in antibody titres and participants\u2019 sera reacted poorly to all peptides spanning SE36.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>BK-SE36\/CpG was well-tolerated and immunogenic. These results pave the way for further proof-of-concept studies to demonstrate vaccine efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=1921<\/jats:ext-link>, PACTR201701001921166.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1267372","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:35:00Z","timestamp":1697434500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and immunogenicity of BK-SE36\/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Alphonse","family":"Ou\u00e9draogo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith Christiane","family":"Bougouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirianne Marie Q.","family":"Palacpac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Houard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Nebie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sawadogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria D.","family":"Berges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issiaka","family":"Soulama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amidou","family":"Diarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Hien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amidou Z.","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadou T.","family":"Konat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seni","family":"Kouanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Myoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Ezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken J.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cousens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181e7fe6c","article-title":"Malaria, a journey in time: in search of the lost myths and forgotten stories","volume":"340","author":"Neghina","year":"2010","journal-title":"Am J Med Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.idc.2004.01.002","article-title":"Malaria: from prehistory to present","volume":"18","author":"Schlagenhauf","year":"2004","journal-title":"Infect Dis Clin North Am"},{"key":"B3","volume-title":"World Malaria Report","year":"2022"},{"key":"B4","unstructured":"GenevaWHOWHO Recommends Groundbreaking Malaria Vaccine for Children at Risk2021"},{"key":"B5","unstructured":"Global Technical Strategy for Malaria 2016-2030, 2021 Update2021"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-022-00937-3","article-title":"RTS,S\/AS01 malaria vaccine (Mosquirix\u00ae): a profile of its use","author":"Syed","year":"2022","journal-title":"Drugs Ther Perspect"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-year efficacy of RTS,S\/AS01 malaria vaccine among young African children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix\u2122): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101072","article-title":"Plasmodium falciparum malaria vaccines and vaccine adjuvants","volume":"9","author":"Bonam","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s41182-023-00516-w","article-title":"Malaria vaccines: the 60-year journey of hope and final success-lessons learned and future prospects","volume":"51","author":"El-Moamly","year":"2023","journal-title":"Trop Med Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medj.2023.07.003","article-title":"Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults","volume":"4","author":"Silk","year":"2023","journal-title":"Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207145200","article-title":"Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth","volume":"277","author":"Aoki","year":"2002","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M206974200","article-title":"A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle","volume":"277","author":"Miller","year":"2002","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.049","article-title":"Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes","volume":"131","author":"Yeoh","year":"2007","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.12941","article-title":"Plasmodium falciparum SERA5 plays a non-enzymatic role in the malarial asexual blood-stage lifecycle","volume":"96","author":"Stallmach","year":"2015","journal-title":"Mol Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2010.05.002","article-title":"Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36","volume":"59","author":"Horii","year":"2010","journal-title":"Parasitol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064073","article-title":"Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36","volume":"8","author":"Palacpac","year":"2013","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978591","article-title":"Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children","volume":"13","author":"Bougouma","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00166-4","article-title":"Aluminum salts in vaccines\u2013US perspective","volume":"20","author":"Baylor","year":"2002","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000893","article-title":"Pediatric vaccine adjuvants: Components of the modern vaccinologist's toolbox","volume":"34","author":"Dowling","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.037","article-title":"Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya","volume":"25","author":"Stoute","year":"2007","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.090","article-title":"Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa","volume":"25","author":"Sirima","year":"2007","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coi.2014.02.003","article-title":"Novel vaccine approaches for protection against intracellular pathogens","volume":"28","author":"Griffiths","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ijpara.2021.01.006","article-title":"A review of combination adjuvants for malaria vaccines: a promising approach for vaccine development","volume":"51","author":"Pirahmadi","year":"2021","journal-title":"Int J Parasitol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22950","article-title":"TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36\/AHG malaria vaccine in nonhuman primate models","volume":"9","author":"Tougan","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.056","article-title":"First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)","volume":"38","author":"Ezoe","year":"2020","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12936-019-2789-8","article-title":"Anopheline species composition and the 1014F-genotype in different ecological settings of Burkina Faso in relation to malaria transmission","volume":"18","author":"Traor\u00e9","year":"2019","journal-title":"Malar J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12936-018-2280-y","article-title":"Spatio-temporal dynamic of malaria in Ouagadougou, Burkina Faso, 2011-2015","volume":"17","author":"Ouedraogo","year":"2018","journal-title":"Malar J"},{"key":"B36","unstructured":"Ouagadougou, Burkina Faso et Rockville, Maryland, USAEnqu\u00eate D\u00e9mographique et de Sant\u00e9 du Burkina Faso 20212022"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5897\/JPHE2022.1409","article-title":"Seasonal malaria chemoprevention coverage in Burkina Faso in 2018: Descriptive analysis of mothers' knowledge and attitude during cross sectional survey","volume":"14","author":"Issaka","year":"2022","journal-title":"J Public Health Epidemiol"},{"key":"B38","unstructured":"Coverage and quality of seasonal malaria chemoprevention supported by Malaria Consortium in 2021: Results from Burkina Faso, Chad, Mozambique, Nigeria, Togo, and Uganda2022"},{"key":"B39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/14760584.2014.863715","article-title":"Recent progress concerning CpG DNA and its use as a vaccine adjuvant","volume":"13","author":"Shirota","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098460","article-title":"Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences","volume":"9","author":"Yagi","year":"2014","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG Adjuvant 1018: A case study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200809030-00001","article-title":"A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases","volume":"9","author":"Gupta","year":"2008","journal-title":"Drugs R D"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.087","article-title":"A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1\/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults","volume":"27","author":"Sagara","year":"2009","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.157","article-title":"Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial","volume":"22","author":"Hodgson","year":"2014","journal-title":"Mol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030267","article-title":"Characteristic of K3 (CpG-ODN) as a transcutaneous vaccine formulation adjuvant","volume":"12","author":"Ito","year":"2020","journal-title":"Pharmaceutics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s12885-022-09818-4","article-title":"(K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study","volume":"22","author":"Otsuka","year":"2022","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002940","article-title":"Phase 1 trial of AMA1-C1\/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria","volume":"3","author":"Mullen","year":"2008","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000172151.28851.fd","article-title":"Antibodies to Plasmodium falciparum antigens vary by age and antigen in children in a malaria-holoendemic area of Kenya","volume":"24","author":"Chelimo","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008787","article-title":"Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1\/Alhydrogel with and without CpG 7909 in malaria na\u00efve adults","volume":"5","author":"Ellis","year":"2010","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022271","article-title":"Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1\/Alhydrogel+CPG 7909","volume":"6","author":"Duncan","year":"2011","journal-title":"PloS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1038\/s41598-018-23194-9","article-title":"Molecular camouflage of Plasmodium falciparum merozoites by binding of host vitronectin to P47 fragment of SERA5","volume":"8","author":"Tougan","year":"2018","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12936-017-1841-9","article-title":"Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine","volume":"16","author":"Greenwood","year":"2017","journal-title":"Malar J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1267372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:35:07Z","timestamp":1697434507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1267372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2023.1267372"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1267372","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"article-number":"1267372"}}